Multiple Sclerosis

1 Recent Advances and Future Challenges in Multiple Sclerosis Clinical Trial Design.- 2 Pathogenesis of Multiple Sclerosis: Relationship to Therapeutic Strategies.- 3 Future of Multiple Sclerosis Therapeutics: Rational Approaches Targeting Putative Pathogenic Mechanisms.- 4 Statistical and Design Considerations for Multiple Sclerosis Clinical Trials.- 5 Clinical Outcome Measures for Multiple Sclerosis.- 6 Use of Neuropsychologic Outcome Measures in Multiple Sclerosis Clinical Trials: Current Status and Strategies for Improving Multiple Sclerosis Clinical Trial Design.- 7 “Quality of Life” Assessment in Multiple Sclerosis Clinical Trials: Current Status and Strategies for Improving Multiple Sclerosis Clinical Trial Design.- 8. Magnetic Resonance Imaging: Current Status and Strategies for Improving Multiple Sclerosis Clinical Trial Design.- 9. Magnetic Resonance Imaging of Patients with Isolated Idiopathic Optic Neuritis, Brainstem Syndromes and Myelopathy.- 10 Strategies to Delay the Onset of Clinically Definite Multiple Sclerosis in Patients with Monosymptomatic Presentations of Optic Neuritis, Brainstem Syndromes or Myelopathy.- 11 Treatment of Multiple Sclerosis with Type I Interferons.- 12 Treatment of Multiple Sclerosis with Methotrexate.- 13 Treatment of Multiple Sclerosis with Copolymer 1.- 14 Treatment of Multiple Sclerosis with Cladribine.- 15 Ethical Considerations Raised by Clinical Trials.- 16 The Emergence of Multiple Sclerosis as a “Treatable” Condition: An Historical Perspective.